Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development.

Autor: Gautam N; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Ramamoorthi G; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Champion N; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Han HS; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Czerniecki BJ; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: brian.czerniecki@moffitt.org.

Publikováno v: Molecular aspects of medicine [Mol Aspects Med] 2024 Feb; Vol. 95, pp. 101239. Date of Electronic Publication: 2023 Dec 26.

Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.

Autor: Ramamoorthi G; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA., Kodumudi K; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA., Snyder C; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA., Grover P; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Zhang H; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Greene MI; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Basu A; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA., Gallen C; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA., Wiener D; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA., Costa RLB; Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Han HS; Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Koski G; Biological Sciences, Kent State University, Kent, Ohio, USA., Czerniecki BJ; Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA brian.czerniecki@moffitt.org.; Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jun; Vol. 10 (6).

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.

Autor: Zachariah NN; Department of Breast Surgery, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Basu A; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Gautam N; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Ramamoorthi G; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Kodumudi KN; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Kumar NB; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Loftus L; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Czerniecki BJ; Department of Breast Surgery, H. Lee Moffitt Cancer Center, Tampa, FL, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2021 Nov 24; Vol. 12, pp. 786286. Date of Electronic Publication: 2021 Nov 24 (Print Publication: 2021).

Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.

Autor: Jia Y; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Breast Oncology, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China., Kodumudi KN; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Ramamoorthi G; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Basu A; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Snyder C; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Wiener D; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Pilon-Thomas S; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Grover P; Department of Pathology and Laboratory Science, Perelman Medical School, University of Pennsylvania, Philadelphia, PA, USA., Zhang H; Department of Pathology and Laboratory Science, Perelman Medical School, University of Pennsylvania, Philadelphia, PA, USA., Greene MI; Department of Pathology and Laboratory Science, Perelman Medical School, University of Pennsylvania, Philadelphia, PA, USA., Mo Q; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Tong Z; Department of Breast Oncology, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China., Chen YZ; Department of Tumor Cell Biology, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China., Costa RLB; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Han H; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Lee C; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Soliman H; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Conejo-Garcia JR; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Koski G; Department of Biologic Sciences, Kent State University, Kent OH, USA., Czerniecki BJ; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: brian.czerniecki@moffitt.org.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2021 Apr 07; Vol. 29 (4), pp. 1541-1556. Date of Electronic Publication: 2021 Jan 05.

PER3 promoter hypermethylation correlates to the progression of pan-cancer.

Autor: Li, Yaoxu^1,2 (AUTHOR), Li, Wenjuan³ (AUTHOR), Deng, Jinhai² (AUTHOR), Yin, Mingzhu^2,4,5 (AUTHOR) yinmingzhu2008@126.com

Publikováno v: Clinical Epigenetics. 10/15/2024, Vol. 16 Issue 1, p1-17. 17p.